AstraZeneca is teaming up with China’s CSPC Pharmaceutical Group to discover and develop new oral drugs, the British-Swedish biopharmaceutical company announced today. Under the deal, CSPC will get an upfront payment of USD110 million and could earn more than USD5.2 billion in development and sales milestone payments.